Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Acquisitions & Divestments: 2016-2021

Historic Change in Acquisitions & Divestments for Akebia Therapeutics (AKBA) over the last 4 years, with Jun 2021 value amounting to $20.0 million.

  • Akebia Therapeutics' Change in Acquisitions & Divestments was N/A to $20.0 million in Q2 2021 from the same period last year, while for Jun 2021 it was $100.2 million, marking a year-over-year change of. This contributed to the annual value of $40.0 million for FY2021, which is 33.60% down from last year.
  • Per Akebia Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $20.0 million for Q2 2021, which was down 0.00% from $20.0 million recorded in Q1 2021.
  • In the past 5 years, Akebia Therapeutics' Change in Acquisitions & Divestments registered a high of $78.7 million during Q1 2019, and its lowest value of $245,000 during Q1 2020.
  • For the 3-year period, Akebia Therapeutics' Change in Acquisitions & Divestments averaged around $31.7 million, with its median value being $23.8 million (2019).
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first plummeted by 99.69% in 2020, then soared by 8,063.27% in 2021.
  • Akebia Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $52.1 million in 2017, then climbed by 21.19% to $63.2 million in 2018, then slumped by 64.39% to $22.5 million in 2019, then soared by 166.67% to $60.0 million in 2020, then soared by 8,063.27% to $20.0 million in 2021.
  • Its last three reported values are $20.0 million in Q2 2021, $20.0 million for Q1 2021, and $60.0 million during Q4 2020.